Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$1.90 USD
+0.01 (0.53%)
Updated May 14, 2024 04:00 PM ET
After-Market: $1.89 -0.01 (-0.53%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
XERS 1.90 +0.01(0.53%)
Will XERS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for XERS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XERS
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
XERS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
Why Xeris (XERS) Might Surprise This Earnings Season
Other News for XERS
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), AMN Healthcare Services (AMN) and 4D Molecular Therapeutics (FDMT)
Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying
Xeris Biopharma price target lowered by $1 at Piper Sandler, here's why
Piper Sandler Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)
Xeris Pharmaceuticals (XERS) Receives a Buy from Oppenheimer